Trial Profile
A PHASE II STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF INTRAVENOUS IDES AFTER ADMINISTRATION OF ASCENDING DOSES IN CHRONIC KIDNEY DISEASE PATIENTS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Imlifidase (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Hansa Biopharma AB; Hansa Medical AB
- 18 Sep 2019 According to a Hansa Biopharma AB media release, pooled data from this and other three studies (244081, 269806 and 305829) were presented at the 19th Congress of the European Society for Organ Transplantation (ESOT) 2019 in Copenhagen, Denmark.
- 12 Mar 2018 Results (n=8) assessing safety and efficacy of IdeS in chronic kidney disease, were published in the American Journal of Transplantation.
- 03 Aug 2017 Combined results of trials ( NCT02224820, NCT02426684, NCT02475551) assessing the efficacy of IdeS with regard to desensitization and transplantation of a kidney from an HLA-incompatible donor.published in the New England Journal of Medicine